Analytical Separation Advances for RNA–LNP Therapeutics

RNA–lipid nanoparticle (LNP) medicines are complex products: their performance depends not only on the RNA sequence but also on RNA integrity, particle properties, and how the therapeutic is associated with or encapsulated by its carrier. In their 2025 critical review, Drennan and Schug examine analytical separation techniques that can help characterize these components and their assembled formulations. The review’s contribution is a structured view of separation science as a complement to commonly used batch measurements, not a report of one new assay or a head-to-head validation study.

Study Background and Research Question

Therapeutic RNA includes oligonucleotides such as small interfering RNA (siRNA), messenger RNA (mRNA), and guide RNA used in CRISPR-based editing. These molecules differ substantially in size, structure, and chemical modification. For example, therapeutic mRNA produced by in vitro transcription (IVT) has a coding region, untranslated regions, a 5′ cap, and a 3′ poly(A) tail. As the review explains, the cap and tail contribute to translation and intracellular stability, while sequence and structural elements also influence RNA function.

Delivery remains a major obstacle: RNA is susceptible to nuclease degradation, and its polyanionic character limits passive passage across cell membranes. LNPs address delivery challenges, but create an analytical challenge of their own. A formulation contains distinct yet interacting components, and a single bulk measurement may not resolve the different particle or RNA populations in a heterogeneous sample.

The review asks how analytical separations can improve characterization and quality control of RNA therapeutics, especially LNP formulations. It considers techniques for RNA alone, LNPs alone, and the RNA–LNP complex. This scope matters because a measurement that reports a sample-wide average may be insufficient when product quality depends on distributions, free versus particle-associated RNA, or other component-level attributes.

Key Innovation from the Reference Study

The review’s key innovation is its analytical framing: separation methods are treated as tools for resolving formulation complexity, rather than as interchangeable replacements for established assays. Drennan and Schug discuss chromatographic, electrophoretic, and field-based approaches alongside methods such as dynamic light scattering (DLS) and modified RiboGreen assays. They identify sample heterogeneity as a significant limitation for common batch-based measurements and describe analytical separations as a way to address questions that bulk readouts may leave unresolved.

This is a critical review, not an experimental paper presenting a new platform with a single set of validated performance metrics. Its value is therefore in organizing current capabilities and challenges across analytical modes. It encourages a multi-attribute view: the RNA, the carrier, and the assembled drug product may each require different measurements, and no individual separation should be assumed to describe every quality attribute.

The authors also situate RNA analysis within broader molecular complexity. For instance, phosphorothioate modifications in oligonucleotides can create stereoisomers, complicating chromatographic resolution. This example illustrates why separation performance depends on the analyte’s chemistry—not simply on choosing a high-resolution instrument. Although this particular issue concerns modified oligonucleotides, the wider lesson applies to the analytical development of diverse RNA medicines.

Methods and Experimental Design Insights

Because the article is a review, it does not prescribe one universal experimental protocol. Instead, it surveys separation families that offer complementary ways to examine RNA–LNP materials. The named areas include liquid chromatography, capillary electrophoresis, field-flow fractionation, and analytical ultracentrifugation. In practical method development, these approaches should be selected according to the question being asked: whether the target is RNA identity or integrity, particle-associated material, particle populations, or a broader comparison of formulation components.

Liquid chromatography and capillary electrophoresis can provide separation-based measurements of molecular species. Their usefulness depends on suitable conditions for the analyte and on controlling interactions with the separation system. Field-flow fractionation and analytical ultracentrifugation offer alternative ways to examine particle or macromolecular populations. The review groups these techniques within a broader characterization toolkit; it does not imply that all methods are equally suited to every RNA sequence, LNP composition, or product-development stage.

Batch-based methods remain useful, but their readouts need careful interpretation. DLS provides information about particle-size behavior in a sample, while modified RiboGreen assays are used to assess RNA in LNP contexts. As the review emphasizes, heterogeneity can limit what such measurements reveal. A distribution or mixture can be compressed into a summary signal, and assay results may depend on sample handling and measurement conditions. Separation can help distinguish components or populations before detection, but it also introduces its own method-development requirements.

For a robust analytical plan, researchers can define the quality question first, then consider orthogonal measurements rather than relying on a single result. For example, a bulk particle measurement and a separation-based readout may answer different questions; agreement between them can strengthen interpretation, while disagreement may flag a sample or method issue that warrants investigation. This is a general workflow recommendation derived from the review’s multi-method perspective, not a specified protocol or acceptance criterion from the authors.

Protocol Parameters

• Study design: Treat the review as a framework for selecting complementary analytical methods; it does not provide a single standardized RNA–LNP assay protocol.
• Analyte definition: Specify whether the target is RNA, LNPs, or the assembled RNA–LNP product before selecting a separation and detection strategy.
• Method comparison: Use batch-based measurements and separation-based methods for distinct, clearly stated analytical questions rather than assuming their readouts are interchangeable.
• Interpretation: Evaluate heterogeneity and possible nonspecific interactions when assessing recovery, resolution, or apparent differences between sample fractions.

Core Findings and Why They Matter

The central finding is that analytical separations are important complements to batch assays for reliable characterization of RNA–LNP therapeutics. The review does not claim that one separation technique solves all characterization problems. Rather, its comparison of chromatographic, electrophoretic, and field-based approaches highlights the need to match the method to the analyte and the intended quality attribute.

That distinction has practical consequences. In a heterogeneous formulation, a mean or aggregate response may not reveal whether different populations are present. Separating material before detection can potentially improve resolution of components or distributions, but a separation result also needs appropriate controls and interpretation. The authors identify nonspecific interactions and limitations in adapting analytical methods to RNA–LNP formulations as important challenges. These concerns make assay development and validation central to the path from research characterization to quality control.

The review also reinforces that RNA drug products cannot be evaluated as RNA alone. Their function depends on an interplay between the molecule and delivery system, while the formulation itself may create analytical artifacts or obscure individual attributes. This supports a multi-attribute characterization strategy: combine measurements that address molecular and particle-level questions, and document what each method can and cannot establish.

Comparison with Existing Internal Articles

The internal article Enhancing RNA Workflows with HyperScribe™ Poly (A) Tailing Kit focuses on preparing polyadenylated IVT RNA for downstream research. It is adjacent to, but distinct from, the review: tailing is an RNA preparation step, whereas Drennan and Schug focus on analytical separation and characterization of RNA, LNPs, and their complexes. Considering both perspectives can help researchers distinguish product preparation from evidence that a formulation has been analytically characterized.

A second related resource, Chemically Modified TPO mRNA Stimulates Thrombopoiesis in Mice, concerns a biological application of modified mRNA. It provides an example of downstream functional research, not evidence validating the separation methods discussed in the review. Together, these resources illustrate why analytical characterization and functional studies answer complementary questions.

Limitations and Transferability

As a critical review, the article synthesizes analytical challenges and advances but does not establish universal method-performance specifications, acceptance limits, or a standard operating procedure. The condensed findings describe technique categories and broad limitations rather than a single controlled comparison across instruments or formulations. Accordingly, readers should consult the full article and relevant method-specific studies before drawing conclusions about performance for a particular product.

Transferability is also constrained by formulation diversity. RNA length and chemistry, LNP composition, sample heterogeneity, and interactions with analytical surfaces or buffers can all affect separation and detection. A method that is useful for one RNA or particle system cannot automatically be assumed to resolve another. Researchers should therefore verify suitability for their own materials, assess recovery and reproducibility, and interpret separation data alongside other measurements. The review’s strongest general recommendation is methodological: use a fit-for-purpose, multi-attribute strategy rather than treating one assay as a complete description of a complex therapeutic.

Research Support Resources

For workflows that require enzymatic polyadenylation after IVT, researchers can use the HyperScribe™ Poly (A) Tailing Kit (SKU K1053), which uses E. coli Poly (A) Polymerase with ATP and is specified to add a tail of at least 150 bases to compatible transcripts generated with the HyperScribe™ T7 High Yield RNA Synthesis Kit. This preparation step may support mRNA stability enhancement and translation efficiency improvement in downstream applications such as transfection experiments, but it does not replace analytical characterization of the resulting RNA or RNA–LNP formulation.